Successful discontinuation of corticosteroids through remission induction therapy with benralizumab for chronic eosinophilic pneumonia

Documenti analoghi

• Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab
  di: Yoshiro Kai, et al.
  Pubblicazione: (2024)
• Successful dabrafenib and trametinib combination therapy in a patient with recurrent BRAFV600E‐mutant non‐small‐cell lung cancer and coexisting radiation pneumonitis
  di: Eriko Nakamura, et al.
  Pubblicazione: (2024)
• Relapsing eosinophilic pneumonia in a patient with recurrent breast cancer receiving abemaciclib plus endocrine therapy
  di: Hiroaki Ogata, et al.
  Pubblicazione: (2024)
• Benralizumab‐resistant mucus plugs in severe asthma complicated by eosinophilic chronic rhinosinusitis
  di: Masamitsu Hamakawa, et al.
  Pubblicazione: (2024)
• Feasibility of continued treatment with dupilumab in patients with type 2 inflammatory disease who developed eosinophilic pneumonia: 3 case reports
  di: Masamitsu Hamakawa, et al.
  Pubblicazione: (2024)